# Mereo BioPharma Group plc: financial statements, quarterly

MREO · Nasdaq · CIK 1719714 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mreo.md) · [Financials](/companies/mreo/financials.md) · [Filings](/companies/mreo/filings.md) · [Insiders](/companies/mreo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mreo/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-124637.md) | [1.0 d](/filings/0000950170-25-044787.md) | [0.0](/filings/0000950170-24-060497.md) | [0.0](/filings/0001193125-25-178489.md) | [0.0](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | not reported | [0.5](/filings/0001193125-26-343533.md) | [0.0](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | not reported | [0.0](/filings/0001193125-26-343533.md) |
| Research and development | $m | [3.6](/filings/0000950170-24-124637.md) | [4.8 d](/filings/0000950170-25-044787.md) | [4.0](/filings/0000950170-25-069816.md) | [4.9](/filings/0001193125-25-178489.md) | [3.2](/filings/0001193125-25-274272.md) | [8.8 d](/filings/0001193125-26-115226.md) | [3.9](/filings/0001193125-26-218232.md) | [5.4](/filings/0001193125-26-343533.md) | [4.3](/filings/0001193125-25-274272.md) | [4.2 d](/filings/0001193125-26-115226.md) | [4.7](/filings/0001193125-26-218232.md) | [1.8](/filings/0001193125-26-343533.md) |
| Operating income | $m | [(9.1)](/filings/0000950170-24-124637.md) | [(7.1) d](/filings/0000950170-25-044787.md) | [(9.9)](/filings/0000950170-25-069816.md) | [(12.8)](/filings/0001193125-25-178489.md) | [(9.4)](/filings/0001193125-25-274272.md) | [(15.3) d](/filings/0001193125-26-115226.md) | [(11.2)](/filings/0001193125-26-218232.md) | [(10.5)](/filings/0001193125-26-343533.md) | [(10.0)](/filings/0001193125-25-274272.md) | [(8.4) d](/filings/0001193125-26-115226.md) | [(8.8)](/filings/0001193125-26-218232.md) | [(7.0)](/filings/0001193125-26-343533.md) |
| Interest expense | $m | [0.7](/filings/0000950170-24-124637.md) | [0.4 d](/filings/0000950170-25-044787.md) | [0.3](/filings/0000950170-25-069816.md) | [0.3](/filings/0001193125-25-178489.md) | [0.4](/filings/0001193125-25-274272.md) | [0.4 d](/filings/0001193125-26-115226.md) | [0.2](/filings/0001193125-26-218232.md) | [0.0](/filings/0001193125-26-343533.md) | [0.0](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | [0.0](/filings/0001193125-26-218232.md) | [0.0](/filings/0001193125-26-343533.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-124637.md) | [(0.5) d](/filings/0000950170-25-044787.md) | [0.0](/filings/0000950170-25-069816.md) | [0.0](/filings/0001193125-25-178489.md) | [0.0](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | [0.0](/filings/0001193125-26-218232.md) | [0.0](/filings/0001193125-26-343533.md) | [0.0](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | [0.0](/filings/0001193125-26-218232.md) | [0.0](/filings/0001193125-26-343533.md) |
| Net income | $m | [(6.5)](/filings/0000950170-24-124637.md) | [(9.1) d](/filings/0000950170-25-044787.md) | [(9.0)](/filings/0001193125-25-274272.md) | [(12.3)](/filings/0001193125-25-274272.md) | [(15.0)](/filings/0001193125-25-274272.md) | [(7.0) d](/filings/0001193125-26-115226.md) | [(12.9)](/filings/0001193125-26-343533.md) | [(14.6)](/filings/0001193125-26-343533.md) | [(7.0)](/filings/0001193125-25-274272.md) | [(7.4) d](/filings/0001193125-26-115226.md) | [(6.7)](/filings/0001193125-26-343533.md) | [(7.0)](/filings/0001193125-26-343533.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0000950170-24-124637.md) | not reported | [(0.01)](/filings/0000950170-25-069816.md) | [(0.02)](/filings/0001193125-25-274272.md) | [(0.02)](/filings/0001193125-25-274272.md) | not reported | [(0.02)](/filings/0001193125-26-218232.md) | [(0.02)](/filings/0001193125-26-343533.md) | [(0.01)](/filings/0001193125-25-274272.md) | not reported | [(0.01)](/filings/0001193125-26-218232.md) | [(0.01)](/filings/0001193125-26-343533.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0000950170-24-124637.md) | not reported | [(0.01)](/filings/0000950170-25-069816.md) | [(0.02)](/filings/0001193125-25-274272.md) | [(0.02)](/filings/0001193125-25-274272.md) | not reported | [(0.02)](/filings/0001193125-26-218232.md) | [(0.02)](/filings/0001193125-26-343533.md) | [(0.01)](/filings/0001193125-25-274272.md) | not reported | [(0.01)](/filings/0001193125-26-218232.md) | [(0.01)](/filings/0001193125-26-343533.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [57.4](/filings/0000950170-25-044787.md) | [48.7](/filings/0000950170-24-060497.md) | [87.4](/filings/0000950170-24-095777.md) | [80.5](/filings/0000950170-24-124637.md) | [69.8](/filings/0001193125-26-115226.md) | [62.5](/filings/0000950170-25-069816.md) | [56.1](/filings/0001193125-25-178489.md) | [48.7](/filings/0001193125-25-274272.md) | [41.0](/filings/0001193125-26-343533.md) | [30.1](/filings/0001193125-26-343533.md) | [30.1](/filings/0001193125-26-343533.md) |
| Current assets | $m | not reported | [63.8](/filings/0000950170-25-044787.md) | [53.5](/filings/0000950170-24-060497.md) | [93.9](/filings/0000950170-24-095777.md) | [86.7](/filings/0000950170-24-124637.md) | [74.8](/filings/0001193125-26-115226.md) | [66.9](/filings/0000950170-25-069816.md) | [61.4](/filings/0001193125-25-178489.md) | [52.4](/filings/0001193125-25-274272.md) | [45.0](/filings/0001193125-26-343533.md) | [40.0](/filings/0001193125-26-218232.md) | [33.4](/filings/0001193125-26-343533.md) |
| Total assets | $m | not reported | [66.5](/filings/0000950170-25-044787.md) | [55.9](/filings/0000950170-24-060497.md) | [96.1](/filings/0000950170-24-095777.md) | [88.7](/filings/0000950170-24-124637.md) | [76.4](/filings/0001193125-26-115226.md) | [68.3](/filings/0000950170-25-069816.md) | [62.6](/filings/0001193125-25-178489.md) | [53.6](/filings/0001193125-25-274272.md) | [45.9](/filings/0001193125-26-343533.md) | [40.6](/filings/0001193125-26-218232.md) | [34.7](/filings/0001193125-26-343533.md) |
| Current liabilities | $m | not reported | [9.5](/filings/0000950170-25-044787.md) | [11.0](/filings/0000950170-24-060497.md) | [15.5](/filings/0000950170-24-095777.md) | [14.2](/filings/0000950170-24-124637.md) | [13.8](/filings/0001193125-26-115226.md) | [7.5](/filings/0000950170-25-069816.md) | [7.6](/filings/0001193125-25-178489.md) | [6.0](/filings/0001193125-25-274272.md) | [4.3](/filings/0001193125-26-343533.md) | [6.2](/filings/0001193125-26-218232.md) | [5.7](/filings/0001193125-26-343533.md) |
| Total liabilities | $m | not reported | [16.0](/filings/0000950170-25-044787.md) | [13.1](/filings/0000950170-24-060497.md) | [17.5](/filings/0000950170-24-095777.md) | [16.2](/filings/0000950170-24-124637.md) | [15.4](/filings/0001193125-26-115226.md) | [8.2](/filings/0000950170-25-069816.md) | [8.5](/filings/0001193125-25-178489.md) | [7.0](/filings/0001193125-25-274272.md) | [5.0](/filings/0001193125-26-343533.md) | [6.6](/filings/0001193125-26-218232.md) | [6.1](/filings/0001193125-26-343533.md) |
| Shareholders' equity | $m | [54.7](/filings/0000950170-24-124637.md) | [50.5](/filings/0001193125-26-115226.md) | [42.8](/filings/0001193125-25-274272.md) | [78.7](/filings/0001193125-25-274272.md) | [(72.5)](/filings/0001193125-25-274272.md) | [61.0](/filings/0001193125-26-343533.md) | [60.1](/filings/0001193125-26-343533.md) | [54.2](/filings/0001193125-26-343533.md) | [46.6](/filings/0001193125-25-274272.md) | [40.9](/filings/0001193125-26-343533.md) | [34.1](/filings/0001193125-26-343533.md) | [28.7](/filings/0001193125-26-343533.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [2,659 d](/filings/0000950170-24-124637.md) | [(6,789) d](/filings/0000950170-25-044787.md) | [(7,991)](/filings/0000950170-25-069816.md) | [(7,904) d](/filings/0001193125-25-178489.md) | [(7,519) d](/filings/0001193125-25-274272.md) | [(9,420) d](/filings/0001193125-26-115226.md) | [(8,329)](/filings/0001193125-26-218232.md) | [(7,651) d](/filings/0001193125-26-343533.md) | [(7,309) d](/filings/0001193125-25-274272.md) | [(7,682) d](/filings/0001193125-26-115226.md) | [(4,312)](/filings/0001193125-26-218232.md) | [(6,043) d](/filings/0001193125-26-343533.md) |
| Capital expenditure | $k | not reported | not reported | [0.0](/filings/0000950170-25-069816.md) | [0.0 d](/filings/0001193125-25-178489.md) | [0.0 d](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | [20.0](/filings/0001193125-26-218232.md) | [0.0 d](/filings/0001193125-26-343533.md) | [0.0 d](/filings/0001193125-25-274272.md) | [0.0 d](/filings/0001193125-26-115226.md) | [0.0](/filings/0001193125-26-218232.md) | [0.0 d](/filings/0001193125-26-343533.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [624](/filings/0000950170-24-060497.md) | [628](/filings/0000950170-24-095777.md) | [685](/filings/0000950170-24-124637.md) | [700](/filings/0000950170-25-069816.md) | [770](/filings/0001193125-25-274272.md) | [770](/filings/0001193125-25-274272.md) | [784](/filings/0001193125-26-218232.md) | [799](/filings/0001193125-26-343533.md) | [800](/filings/0001193125-25-274272.md) | [802](/filings/0001193125-26-218232.md) | [804](/filings/0001193125-26-343533.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 798,454,864 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-343533.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.